JP2017518260A5 - - Google Patents

Download PDF

Info

Publication number
JP2017518260A5
JP2017518260A5 JP2016558558A JP2016558558A JP2017518260A5 JP 2017518260 A5 JP2017518260 A5 JP 2017518260A5 JP 2016558558 A JP2016558558 A JP 2016558558A JP 2016558558 A JP2016558558 A JP 2016558558A JP 2017518260 A5 JP2017518260 A5 JP 2017518260A5
Authority
JP
Japan
Prior art keywords
sequence
seq
fragment
mab
tkleik
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016558558A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017518260A (ja
JP6740135B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2015/026595 external-priority patent/WO2015161311A2/en
Publication of JP2017518260A publication Critical patent/JP2017518260A/ja
Publication of JP2017518260A5 publication Critical patent/JP2017518260A5/ja
Application granted granted Critical
Publication of JP6740135B2 publication Critical patent/JP6740135B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016558558A 2014-04-18 2015-04-20 ヒト化抗−ｔｆ−抗原抗体 Active JP6740135B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461981240P 2014-04-18 2014-04-18
US61/981,240 2014-04-18
PCT/US2015/026595 WO2015161311A2 (en) 2014-04-18 2015-04-20 Humanized anti-tf-antigen antibodies

Publications (3)

Publication Number Publication Date
JP2017518260A JP2017518260A (ja) 2017-07-06
JP2017518260A5 true JP2017518260A5 (OSRAM) 2018-05-31
JP6740135B2 JP6740135B2 (ja) 2020-08-12

Family

ID=54324717

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016558558A Active JP6740135B2 (ja) 2014-04-18 2015-04-20 ヒト化抗−ｔｆ−抗原抗体

Country Status (11)

Country Link
US (1) US11130821B2 (OSRAM)
EP (2) EP3131581B1 (OSRAM)
JP (1) JP6740135B2 (OSRAM)
KR (1) KR102413809B1 (OSRAM)
CN (1) CN106488774B (OSRAM)
AU (1) AU2015247358B2 (OSRAM)
BR (1) BR112016024214B8 (OSRAM)
ES (1) ES2843546T3 (OSRAM)
MX (2) MX378944B (OSRAM)
RU (1) RU2699717C2 (OSRAM)
WO (1) WO2015161311A2 (OSRAM)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3058134A1 (en) * 2017-04-13 2018-10-18 Aduro Biotech Holdings, Europe B.V. Anti-sirp alpha antibodies
MA50195A (fr) * 2017-09-22 2020-07-29 Immunogen Inc Séparation d'anticorps à chaîne triple légère à l'aide d'une chromatographie à échange de cations
KR20200138288A (ko) * 2018-03-28 2020-12-09 미쓰비시 타나베 파마 코퍼레이션 cMET 모노클로날 결합제의 약물 접합체, 및 그의 용도
CA3100896C (en) 2018-05-30 2023-08-29 National Health Research Institutes Anti-abeta antibodies and uses thereof
EP3898677A1 (en) 2018-12-21 2021-10-27 OSE Immunotherapeutics Bifunctional anti-pd-1/il-7 molecule
SG11202106347PA (en) 2018-12-21 2021-07-29 Ose Immunotherapeutics Humanized anti-human-pd-1 antibody
EP3898676A1 (en) 2018-12-21 2021-10-27 OSE Immunotherapeutics Bifunctional anti-pd-1/sirpa molecule
CN113573782B (zh) 2018-12-21 2025-12-16 Ose免疫疗法公司 针对人pd-1的双功能分子
WO2020165374A1 (en) 2019-02-14 2020-08-20 Ose Immunotherapeutics Bifunctional molecule comprising il-15ra
MX2022011701A (es) * 2020-03-23 2022-10-07 Bristol Myers Squibb Co Anticuerpos anti-receptor de quimiocina 8 con motivo c-c (ccr8) para el tratamiento del cancer.

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050260680A1 (en) * 2004-04-16 2005-11-24 Vanderbilt University Methods of diagnosing and treating autoimmune diseases
WO2006012616A2 (en) 2004-07-26 2006-02-02 The Research Foundation Of State University Of New York At Buffalo Stor Intellectual Property Division Therapeutic use of anti-tf-antigen antibody
GB0510790D0 (en) * 2005-05-26 2005-06-29 Syngenta Crop Protection Ag Anti-CD16 binding molecules
WO2007109747A2 (en) 2006-03-21 2007-09-27 Wyeth Methods and compositions for antagonism of rage
EP2161031A1 (en) * 2008-09-05 2010-03-10 SuppreMol GmbH Fc gamma receptor for the treatment of B cell mediated multiple sclerosis
PT2488551T (pt) * 2009-10-16 2018-10-31 Inst Nat Sante Rech Med Anticorpos monoclonais contra a progastrina e suas utilizações
EP2347769A1 (en) * 2010-01-20 2011-07-27 Glycotope GmbH Cancer stem cell markers and uses thereof
EP2407487A1 (en) 2010-07-14 2012-01-18 F-Star Biotechnologische Forschungs - und Entwicklungsges. M.B.H. Multispecific modular antibody
AU2012245116A1 (en) 2011-04-20 2013-11-07 Genmab A/S Bispecific antibodies against HER2 and CD3
EP2787081A4 (en) * 2011-11-30 2015-10-07 Chugai Pharmaceutical Co Ltd PHARMACEUTICAL CARRIER IN CELLS FOR THE FORMATION OF AN IMMUNOMOPLEX
CN102796144A (zh) * 2012-08-22 2012-11-28 山东大学 Tf抗原及其类似物、和其化学酶法合成方法及其应用
US10023651B2 (en) * 2014-04-18 2018-07-17 The Research Foundation For The State University Of New York Humanized anti-TF-antigen antibodies

Similar Documents

Publication Publication Date Title
JP2017518260A5 (OSRAM)
PE20180480A1 (es) Anticuerpos de factor xi y metodos de uso
RU2016143552A (ru) Гуманизированные антитела к антигену Томсена-Фриденрайха
PE20180046A1 (es) Anticuerpos terapeuticos y sus usos
EA201792221A1 (ru) Антитела против сортилина и способы их применения
WO2017075432A3 (en) Anti-siglec-9 antibodies and methods of use thereof
MX2019013033A (es) Formulaciones estables de anticuerpos anti-tigit solos y en combinacion con anticuerpos anti-receptor de muerte programada 1 (pd-1) y metodos para su uso.
WO2016201389A3 (en) Anti-cd33 antibodies and methods of use thereof
WO2016201388A3 (en) Anti-cd33 antibodies and methods of use thereof
CL2018003608A1 (es) Anticuerpo aislado o fragmento de unión a antígeno del mismo que se une específicamente interleucina-25 hjumana (il-2525); composición farmacéutica que lo comprende; uso de dicha composición farmacéutica para tratar una enfermedad o trastorno asociado con la actividad o expresión de il-25. (divisional solicitud 201700703)
JOP20190236A1 (ar) أجسام مضادة لـ ilt4 وشظايا ارتباط بمولد ضد
PH12018500295A1 (en) Chimeric antigen receptors based on single-domain antibodies and methods of use thereof
EA201791666A1 (ru) Антитела к cd3, антитела к cd123 и биспецифические антитела, которые специфически связываются с cd3 и/или cd123
PE20171180A1 (es) Anticuerpos anti-pd-1 y sus metodos de uso
WO2017062672A3 (en) Anti-trem2 antibodies and methods of use thereof
PE20191487A1 (es) Anticuerpos anti-gitr y metodos de uso de los mismos
PE20181054A1 (es) Anticuerpos anti-cd19 humano humanizados y metodos de utilizacion
HRP20200034T1 (hr) Monoklonska protutijela protiv čimbenika rasta i diferencijacije 15 (gdf-15), te njihova upotreba u liječenju kaheksije uzrokovane rakom i raka
EA201790342A1 (ru) Антитела к trem2 и способы их применения
ES2776179T3 (es) Anticuerpos dirigidos contra determinantes de la superficie de S. aureus
CA2886433C (en) Human monoclonal anti-pd-l1 antibodies and methods of use
EA202091590A1 (ru) Антитела против pd-l1 и варианты их применения
MX2018006333A (es) Anticuerpos anti-receptor de muerte 5 (dr5) y metodos de uso de los mismos.
IL291545A (en) Anti-ctla4 antibodies, antibody fragments, their immunoconjugates and uses thereof
AR096617A1 (es) Anticuerpos anti-tweakr y sus usos